Class II transactivator (CIITA) mediates transcriptional repression of pdk4 gene by interacting with hypermethylated in cancer 1 (HIC1)

Journal of Biomedical Research

Volumn 29, Issue 4, 2015, Pages 308-315

  Fang, Mingming ^a   Li, Ping ^a,b   Wu, Xiaoyan ^a,c   Xu, Yong ^a,c  

^a Jiangsu Jiankang Vocational Institute   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CIITA; HIC; IFN gamma; PDK4; SIRT1; Transcriptional regulation

Indexed keywords

CELL PROTEIN; CLASS II TRANSACTIVATOR; GAMMA INTERFERON; HYPERMETHYLATED IN CANCER 1; PYRUVATE DEHYDROGENASE KINASE 4; SILENT INFORMATION REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; REGULATORY MECHANISM; REPORTER GENE; SKELETAL MUSCLE;

EID: 84941198921     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.29.20150055     Document Type: Article

References (44)

1. Magkos F, Yannakoulia M, Chan JL, et al. Management of the metabolic syndrome and type 2 diabetes through[J]. Annu Rev Nutr, 2009;29:223-256.
2. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology[J]. JAMA, 2009;301(20):2129-2140.
3. Hotamisligil GS. Inflammation and metabolic disorders[J]. Nature, 2006;444(7121):860-867.
4. Brenner C, Galluzzi L, Kepp O, et al. Decoding cell death signals in liver inflammation[J]. J Hepatol, 2013; 59(3):583-594.
5. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice[J]. Cardiovasc Res, 2008;79(3):360-376.
6. Chow EK,RazaniB,Cheng G. Innate immune system regulation of nuclear hormone receptors in metabolic diseases[J]. J Leukoc Biol, 2007;82(2):187-195.
7. Magkos F, Yannakoulia M, Chan JL, et al. Management of the metabolic syndrome and type 2 diabetes through[J]. Annu Rev Nutr, 2009;29:223-256.
8. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology[J]. JAMA, 2009;301(20):2129-2140.
9. Hotamisligil GS. Inflammation and metabolic disorders[J]. Nature, 2006;444(7121):860-867.
10. Brenner C, Galluzzi L, Kepp O, et al. Decoding cell death signals in liver inflammation[J]. J Hepatol, 2013; 59(3):583-594.
11. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice[J]. Cardiovasc Res, 2008;79(3):360-376.
12. Chow EK,RazaniB,Cheng G. Innate immune system regulation of nuclear hormone receptors in metabolic diseases[J]. J Leukoc Biol, 2007;82(2):187-195.
13. Fang M et al. J Biomed Res, 2015; 29(4):308-315
14. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes[J]. Nature, 2007;450(7170):712-716.
15. Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice[J]. Cell Metab, 2008;8(4):333-341.
16. Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation[J]. Cell Metab, 2009;9(4):327-338.
17. Purushotham A, Xu Q, Li X. Systemic SIRT1 insufficiency results in disruption of energy homeostasis and steroid hormone metabolism upon high-fat-diet feeding[J]. FASEB J, 2012;26(2):656-667.
18. Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation[J]. Cell Metab, 2008;8(5):347-358.
19. Li P, Zhao Y, Wu X, et al. Interferon gamma (IFNgamma) disrupts energy expenditure and metabolic homeostasis by suppressing SIRT1 transcription[J]. Nucleic Acids Res, 2012;40(4):1609-1620.
20. Kwon HS, Huang B, Ho Jeoung N, et al. Retinoic acids and trichostatin A (TSA), a histone deacetylase inhibitor, induce human pyruvate dehydrogenase kinase 4 (PDK4) gene expression[J]. Biochim Biophys Acta, 2006;1759(3-4):141-151.
21. Wu X, Kong X, Chen D, et al. SIRT1 links CIITA deacetylation to MHC II activation[J]. Nucleic Acids Res, 2011;39(22):9549-9558.
22. Fang M, Kong X, Li P, et al. RFXB and its splice variant RFXBSV mediate the antagonism between IFNgamma and TGFbeta on COL1A2 transcription in vascular smooth muscle cells[J]. Nucleic Acids Res, 2009;37(13):4393-4406.
23. Pinte S, Stankovic-Valentin N, Deltour S, et al. The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties[J]. J Biol Chem, 2004;279(37):38313-38324.
24. Brestoff JR, Artis D. Immune Regulation of Metabolic Homeostasis in Health and Disease[J]. Cell, 2015;161(1): 146-160.
25. McGillicuddy FC, Chiquoine EH, Hinkle CC, et al. Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway[J]. J Biol Chem, 2009;284(46):31936-31944.
26. Wensveen FM, Jelencic V, Valentic S, et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance[J]. Nat Immunol, 2015;16(4):376-385.
27. Rocha VZ, Folco EJ, Sukhova G, et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity[J]. Circ Res, 2008; 103(5):467-476.
28. Wong N, Fam BC, Cempako GR, et al. Deficiency in interferon-gamma results in reduced body weight and better glucose tolerance in mice[J]. Endocrinology, 2011;152(10):3690-3699.
29. Pacifico L, Di Renzo L, Anania C, et al. Increased T-helper interferon-gamma-secreting cells in obese children[J]. Eur J Endocrinol, 2006;154(5): 691-697.
30. Schmidt FM, Weschenfelder J, Sander C, et al. Inflammatory cytokines in general and central obesity and modulating effects of physical activity[J]. Plos One, 2015;10(3):e0121971.
31. Utsal L, Tillmann V, Zilmer M, et al. Elevated serum IL-6, IL-8, MCP-1, CRP, and IFN-gamma levels in 10-to 11-year-old boys with increased BMI[J]. Horm Res Paediatr, 2012;78(1):31-39.
32. Surendar J, Mohan V, Rao MM, et al. Increased levels of both Th1 and Th2 cytokines in subjects with metabolic syndrome (CURES-103) [J]. Diabetes Technol Ther, 2011;13(4):477-482.
33. Wu X, Kong X, Luchsinger L, et al. Regulating the activity of class II transactivator by posttranslational modifications: exploring the possibilities[J]. Mol Cell Biol, 2009;29(21):5639-5644.
34. Harton JA, Cressman DE, Chin KC, et al. GTP binding by class II transactivator: role in nuclear import[J]. Science, 1999;285(5432):1402-1405.
35. Xu Y, Harton JA, Smith BD. CIITA mediates interferongamma repression of collagen transcription through phosphorylation dependent interactions with co-repressor molecules[J]. J Biol Chem, 2008;283(3):1243-1256.
36. Zika E, Fauquier L, Vandel L, et al. Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression[J]. Proc Natl Acad Sci U S A, 2005;102(45):16321-16326.
37. Zhou X, Jiang Y, Lu L, et al. MHC class II transactivator represses human IL-4 gene transcription by interruption of promoter binding with CBP/p300, STAT6 and NFAT1 via histone hypoacetylation[J]. Immunology, 2007; 122(4):476-485.
38. Kong X, Fang M, Li P, et al. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells[J]. J Mol Cell Cardiol, 2009;46(3):292-299.
39. Linhoff MW, Harton JA, Cressman DE, et al. Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains[J]. Mol Cell Biol, 2001;21(9):3001-3011.
40. Deng T, Lyon CJ, Minze LJ, et al. Class II major histocompatibility complex plays an essential role in obesityinduced adipose inflammation[J]. Cell Metab, 2013;17(3):411-422.
41. Mohammad HP, Zhang W, Prevas HS, et al. Loss of a single Hic1 allele accelerates polyp formation in Apc(Delta716) mice[J]. Oncogene, 2011;30(23):2659-2669.
42. Pinte S, Guerardel C, Deltour-Balerdi S, et al. Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1[J]. Oncogene, 2004;23(22):4023-4031.
43. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression[J]. Annu Rev Immunol, 2001;19:331-373.
44. Xu Y, Ravid K, Smith BD. Major histocompatibility class II transactivator expression in smooth muscle cells from A2b adenosine receptor knock-out mice: crosstalk between the adenosine and interferon-gamma signaling[J]. J Biol Chem, 2008;283(21):14213-14220.